Thyroid cancer is diagnosed in approximately 45,240 Americans annually and carries an overall five-year survival of 98.5% — one of the highest of any malignancy. That figure, however, obscures meaningful variation. Incidence has risen 250% since 1990 while mortality has held flat, reflecting widespread detection of small papillary microcarcinomas that often require no immediate intervention. At the same time, anaplastic thyroid cancer carries a median survival of three to five months, and older adults face incidence-based mortality ten times higher than younger patients. Across all subtypes, the central clinical task is the same: accurate risk stratification over reflexive action.
AAVBC's Thyroid Cancer Quick Reference Guide supports that judgment with a structured clinical and documentation reference. It covers histologic subtype recognition, the 2025 ATA DATA framework for shared decision-making, active surveillance criteria, ICD-10 coding, post-treatment hypothyroidism and hypoparathyroidism documentation, TSH suppression targets, metastatic site coding, and MEAT standards — grounded in current ATA guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of thyroid cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Thyroid cancer is diagnosed in approximately 45,240 Americans annually and carries an overall five-year survival of 98.5% — one of the highest of any malignancy. That figure, however, obscures meaningful variation. Incidence has risen 250% since 1990 while mortality has held flat, reflecting widespread detection of small papillary microcarcinomas that often require no immediate intervention. At the same time, anaplastic thyroid cancer carries a median survival of three to five months, and older adults face incidence-based mortality ten times higher than younger patients. Across all subtypes, the central clinical task is the same: accurate risk stratification over reflexive action.
AAVBC's Thyroid Cancer Quick Reference Guide supports that judgment with a structured clinical and documentation reference. It covers histologic subtype recognition, the 2025 ATA DATA framework for shared decision-making, active surveillance criteria, ICD-10 coding, post-treatment hypothyroidism and hypoparathyroidism documentation, TSH suppression targets, metastatic site coding, and MEAT standards — grounded in current ATA guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of thyroid cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
